

DRUG UTILIZATION REVIEW BOARD MEETING
May 12, 2009
205 JEFFERSON STREET
JEFFERSON CITY, MO 65101

Board Members Present by Phone:

John Newcomer, MD, Chairman
 Jennifer Passanise, FNP
 Charlene Heyde, RPh
 Sandra Bollinger, PharmD
 Sharad Parikh, M.D.
 David Campbell, M.D
 Joseph Yasso, DO

MO HealthNet Division Staff Present:

George L. Oestreich, PharmD, Deputy Division Director
 Rhonda Driver, RPh, Director Pharmacy Program
 Jay Bryant-Wimp, RPh, Clinical Pharmacist
 Allison Lauf, RN
 Jayne Zemmer, Program Manager
 Beth McQuaide, Administrative Assistant
 Mary Heet, RN

Board Members Absent:

Peggy Wanner-Barjenbruch, MD
 Joy Gronstedt, DO
 Randy Becker, PharmD
 Susan Abdel-Rahman, PharmD
 Stacy Mangum, PharmD

Others Attending:

M. Patty Laster, Genentech Inc
 Eric Blake, Schering Plough
 C. Wycinowski, Pfizer
 Carol Curtis, Astra Zeneca
 M Kloos, Pfizer
 C. Wycinowski, Pfizer
 Lon Lowry, Novartis
 Gamal Collier, Novartis
 R. Kilo, Pfizer

Welcome, Introductions and Opening Remarks	Chairman, John Newcomer, M.D. called the conference call to order at 3:00 p.m. A quorum was established by roll call (See roll call votes). Dr. Newcomer summarized why the conference call had been called and noted the two items on the agenda for the call were to ratify the recommendations made by the Committee of the Whole at the April 15, 2009 meeting and to discuss in more detail the PDL recommendation for the Statin drug class.
Minutes Approval	Draft minutes of the April 15, 2009 meeting were e-mailed to all members prior to the conference call. These minutes were reviewed and approved as submitted. By approval of the minutes the Drug Utilization Review (DUR) Board ratified all recommendations made by the Committee of the Whole.
Statins	<ul style="list-style-type: none"> • Discussion-Dr. Newcomer reminded members who attended the April 15, 2009 meeting and updated those who were not in attendance on the discussion surrounding this class and the specifics of the Preferred Drug List (PDL) recommendation under discussion, in particular the movement of two high potency agents to non-preferred status. This discussion included seeking seamless approval, for secondary prevention needs, using data readily available and captured electronically. Discussion ensued regarding what these criteria should be. Rhonda Driver, RPh, Director Pharmacy Program stated that other clinical edits have similar criteria attached and it would not be difficult to build this clinical arm into the Statin PDL edit. She also reminded the group that when a call to the help desk is required it is a real time process. Members also discussed the possibility of allowing transparent, first line approval for high dose non preferred agents, however determined, after discussion of utilization numbers, that this was not necessary. • Decision-Following the discussion the motion to approve the Statin PDL recommendation with the modification to allow transparent access to non preferred agents for those participants that meet defined or inferred diagnostic criteria was made, seconded and passed. (See roll call votes)
Adjourn	The call adjourned at approximately 3:40 p.m. MO HealthNet staff responded to several questions from audience members including a short budget update and clarification of trial and failure language in the Inhaled Corticosteroid edit.

Roll Call Votes – May 12, 2009

Member	Attendance	April 15, 2009 Minutes	Statins
Susan Abdel-Rahman	<i>Absent</i>	Absent	Absent
Randy Beckner	<i>Absent</i>	Absent	Absent
Sandra Bollinger	<i>Yeah</i>	Yeah	Second
Jennifer Passanise	Yeah	Motion	Yeah
David Campbell	<i>Yeah</i>	Yeah	Yeah
Joy S. Gronstedt	<i>Absent</i>	Absent	Absent
Stacy Mangum	<i>Absent</i>	Absent	Absent
John Newcomer	Yeah	Yeah	Yeah
Sharad Parikh	Yeah	Second	Yeah
Charlene Heyde	Yeah	<i>Yeah</i>	Yeah
Peggy Wanner- Barjenbruch	Absent	Absent	Absent
Joseph M. Yasso	Yeah	Yeah	Motion